ClinicalTrials.gg
Enrolling by invitationNCT06467110Updated Jun 20, 2024

Safety and Effectiveness Study of SQ-Kyrin TMVr System for Degenerated Mitral Regurgitation

An interventional study of transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical) in Degenerated Mitral Regurgitation, sponsored by Shanghai Shenqi Medical Technology Co., Ltd. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by Shanghai Shenqi Medical Technology Co., Ltd · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as enrolling by invitation.
  • Registered 2 years 7 months after the study started (first participant enrolled Oct 2021, registered Jun 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
118
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Mitral Valve Insufficiency with a site in China — 44 open to participants now, 46 under way, none of them phase 3. Mitral Valve Insufficiency · China.

Planned enrollment
26th of 40
118 · median 127
Started
2021
with 6 others
No phase
36 of 57
29 open now
Primary completion
2024-12
later than 12 of 45 live
Registered
32nd of 57
by date
Lead sponsor
3 of 57
Shanghai Shenqi Medical Technology Co., Ltd

Among the 57 studies in Mitral Valve Insufficiency with a site in China, this one is the 26th largest by planned enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2021, is one of 36 with no phase, reaches primary completion later than 12 of the 45 other live ones, and was the 32nd registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

44 of the 57 studies in Mitral Valve Insufficiency with a site in China are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Mitral Valve Insufficiency with a site in China, or all of them as a file.
02

Study summary

To verify the safety and effectiveness of transcatheter mitral valve clip delivery system and steerable guide catheter produced by Shanghai Shenqi Medical Technology Co., Ltd.in patients with moderate-severe or severe degenerated mitral regurgitation (DMR).

Read the detailed description

This study is clinical research using a prospective, multicenter, single arm method to evaluate the safety and effectiveness of transcatheter mitral valve clip delivery system and steerable guide catheter transcatheter mitral valve clip delivery system and steerable guide catheter in the treatment of patients with moderate-severe (3+) or severe (4+) degenerated mitral regurgitation. A total of 118 subjects are planned to be included in this trial. All subjects are treated with transcatheter mitral valve clip delivery system and steerable guide catheter transcatheter mitral valve clip delivery system and steerable guide catheter, and are followed up at 30 days, 6 months and 12 months after surgery. At the follow-up of 12 months after surgery, the composite endpoints of no death, no surgical mitral valve related surgery due to mitral valve dysfunction, and no moderate-severe or severe MR (MR > 2 +) are evaluated. After the follow-up of 12 months after surgery, the stage statistical analysis, clinical summary and application for product registration are performed.

03

Conditions studied

  • Degenerated Mitral Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe MR ≥3+ as determined by transthoracic echocardiography (TTE);
  • STS risk score results show that patients at high risk for traditional surgery or patients who cannot tolerate traditional thoracotomy: Subjects judged to be to mitral valve surgery due to a ≥ 8% risk of death from STS surgery for surgical mitral valve replacement, or a ≥ 6% risk of death from STS surgery for surgical mitral valve repair, or because of any of the following risk factors:

    1. Porcelain aorta or active ascending aortic plaque
    2. Mediastinum treated with radiotherapy
    3. Past mediastinitis
    4. (LVEF) \<40%
    5. Presence of a patent coronary bypass implant
    6. Acceptance of two or more cardiothoracic surgeries
    7. Liver cirrhosis
    8. Other surgical risk factors
  • Patients with Degenerated MR (Degenerated MR);
  • Age ≥ 18 years old, regardless of gender;
  • Classification of cardiac function: class II, III or ambulatory class IV;
  • Patients assessed by a multidisciplinary cardiac team as very high-risk or unsuitable for routine mitral valve surgery;
  • Be able to understand the objective of the trial, and volunteered to participate and signed the Form, willing to accept the relevant examination and clinical follow-up.
  • Left ventricular end-systolic diameter (LVESD)≤60mm
  • The MR beam mainly originates from the A2/P2 area
  • Mitral valve disease prolapse lesion area width≤15mm, prolapse height≤10mm, effective length of anterior and posterior valve leaflets>10mm
  • Mitral valve effective orifice area (EOA) ≥ 4.0cm2
  • No obvious calcification of mitral valve leaflets
  • Patient anatomy allows atrial septum approach

Exclusion criteria

Exclusion Criteria:

  • History of mitral valve surgery;
  • Patients with infective endocarditis or suggestive of active infection;
  • Complicated with severe untreated coronary artery disease;
  • Patients with pulmonary hypertension (pulmonary systolic blood pressure>70mmHg);
  • Patients with transthoracic echocardiographic evidence suggesting moderate-severe to severe right ventricular dysfunction;
  • \<20%;
  • Patients who are extremely frail and cannot tolerate general anesthesia surgery or is in the state of shock requiring circulatory support;
  • Patients diagnosed with hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis;
  • Mitral regurgitation due to active rheumatic heart disease or rheumatic etiology;
  • Severe renal insufficiency ( ≤ 25 mL/min) or requiring chronic renal replacement therapy;
  • Patients with definite coagulation disorders and severe coagulation system diseases;
  • Patients with clear to the use of anticoagulants;
  • Patients with stroke or transient cerebral ischemic attack within 30 days;
  • Any intracardiac mass, left ventricular or atrial thrombus detected on transthoracic echocardiography;
  • Severe tricuspid TR;
  • Patients with other valve disease requiring surgery or interventional therapy;
  • Patients with severe macrovascular disease requiring surgical treatment;
  • Severe symptomatic carotid stenosis (>70% on ultrasonography) or carotid stenting within 30 days;
  • Patients with inappropriate anatomical structures of the heart and valves indicated by imaging examinations;
  • Known allergy to contrast agents and nickel-titanium memory alloy products;
  • R\<testing systolic blood pressure 90 mmHg or >160 mmHg;
  • Patients with diseases that seriously affect the evaluation of treatment, such as patients with severe neurological lesions affecting cognitive ability, patients with malignant tumors, etc.;
  • Patient \< 12 months;
  • Patients with severe thoracic deformity;
  • Women who are pregnant, breastfeeding, or planning to become pregnant within the next 12 months.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)

    The principle of this product is the transcatheter interventional edge-to-edge repair technology (edge-to-edge repair). The core technology is to treat the regurgitation by edge-to-edge suturing the mitral valve. The double holes are set in the mitral valve (A2/P2 zone) or the edges in A1/P1 or A3/P3 zones are apposed and closed to treat regurgitation.

    Device: transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)

Interventions

  • Devicetranscatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)

    The principle of this product is the transcatheter interventional edge-to-edge repair technology (edge-to-edge repair). The core technology is to treat the regurgitation by edge-to-edge suturing the mitral valve. The double holes are set in the mitral valve (A2/P2 zone) or the edges in A1/P1 or A3/P3 zones are apposed and closed to treat regurgitation.

06

What researchers measure

Primary outcomes

  1. 1. Incidence of composite endpoint of no death, no surgical mitral valve-related procedures due to mitral valve dysfunction, and no moderate-severe or severe MR (MR>2+) at 12 months after surgery

    Incidence of composite endpoint of no death, no surgical mitral valve-related procedures due to mitral valve dysfunction, and no moderate-severe or severe MR (MR\>2+) at 12 months after surgery

    Time frame: 12 months after surgery

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Dec 2024, 38 months after the start.

Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 38 months is below that.

Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 20, 2024
StartActual
Oct 15, 2021
Primary completionEst.
Dec 15, 2024
CompletionEst.
Dec 15, 2028
Last update
Jun 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06467110
Lead sponsor
Shanghai Shenqi Medical Technology Co., Ltd
Responsible party
Sponsor
First posted
Jun 20, 2024
Start date
Oct 15, 2021
Primary completion
Dec 15, 2024 (estimated)
Completion
Dec 15, 2028 (estimated)
Last update
Jun 20, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion